UK markets close in 4 hours 9 minutes
  • FTSE 100

    5,821.52
    -67.70 (-1.15%)
     
  • FTSE 250

    17,828.17
    -101.03 (-0.56%)
     
  • AIM

    970.40
    -2.54 (-0.26%)
     
  • GBP/EUR

    1.1005
    +0.0061 (+0.56%)
     
  • GBP/USD

    1.3050
    +0.0104 (+0.80%)
     
  • BTC-GBP

    9,368.96
    +834.62 (+9.78%)
     
  • CMC Crypto 200

    245.56
    +6.65 (+2.78%)
     
  • S&P 500

    3,443.12
    +16.20 (+0.47%)
     
  • DOW

    28,308.79
    +113.37 (+0.40%)
     
  • CRUDE OIL

    40.98
    -0.72 (-1.73%)
     
  • GOLD FUTURES

    1,922.60
    +7.20 (+0.38%)
     
  • NIKKEI 225

    23,639.46
    +72.42 (+0.31%)
     
  • HANG SENG

    24,754.42
    +184.88 (+0.75%)
     
  • DAX

    12,638.81
    -98.14 (-0.77%)
     
  • CAC 40

    4,882.62
    -46.66 (-0.95%)
     

If You Had Bought Europlasma (EPA:ALEUP) Stock Five Years Ago, You'd Be Sitting On A 99% Loss, Today

Simply Wall St
·3-min read

Europlasma S.A. (EPA:ALEUP) shareholders will doubtless be very grateful to see the share price up 213% in the last week. But will that repair the damage for the weary investors who have owned this stock as it declined over half a decade? Probably not. Like a ship taking on water, the share price has sunk 99% in that time. The recent bounce might mean the long decline is over, but we are not confident. The fundamental business performance will ultimately determine if the turnaround can be sustained.

We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.

Check out our latest analysis for Europlasma

Europlasma isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last half decade, Europlasma saw its revenue increase by 0.6% per year. That's far from impressive given all the money it is losing. It's not so sure that share price crash of 64% per year is completely deserved, but the market is doubtless disappointed. We'd be pretty cautious about this one, although the sell-off may be too severe. We'd recommend focussing any further research on the likelihood of profitability in the foreseeable future, given the muted revenue growth.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

ENXTPA:ALEUP Income Statement, February 20th 2020
ENXTPA:ALEUP Income Statement, February 20th 2020

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

A Different Perspective

Europlasma shareholders are down 82% for the year, but the market itself is up 21%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 64% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Europlasma has 6 warning signs (and 4 which are concerning) we think you should know about.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on FR exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.